NCT00586599已完成不适用
Levels of the Stat4 Alpha and Stat4 Beta Isoforms in PBMCs From Patients With Crohn's Disease and Ulcerative Colitis
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 51
- 试验地点
- 2
- 主要终点
- This study hopes to assess the relative levels of the Stat4a and Stat4β isoforms in PBMCs from patients with Crohn's Disease, ulcerative colitis, or from control patients.
研究概览
简要总结
The goal in these studies will be to assess the relative levels of the Stat4 alpha and Stat4 beta isoforms in PBMCs from patients with Crohn's Disease, ulcerative colitis, celiac disease or from control patients. We hypothesize that the beta to alpha ratio will be higher in patients with active disease and that there will be a correlation between the ratio and the severity of disease.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 盲法
- None
入排标准
- 年龄范围
- 7 Years 至 17 Years（Child）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Children with a new diagnosis of Crohn's Disease and whose physician has not yet initiated corticosteroid treatment (10 Subjects):
- •Clinical diagnosis within the previous 21 days
- •Above age 7 and younger than age 18
- •Signed informed consent statement and assent statement.
- •Children with a new diagnosis of Ulcerative Colitis and whose physician has not yet initiated corticosteroid treatment (10 Subjects):
- •Clinical diagnosis within the previous 21 days
- •Above age 7 and younger than age 18
- •Signed informed consent statement and assent statement.
- •Children with Crohn's Disease whose physician has initiated Infliximab treatment for the first time (10 Subjects):
- •Clinical diagnosis of Crohn's Disease
- •Above age 7 and younger that age 18
- •Signed informed consent statement and assent statement.
- •Children with Ulcerative Colitis whose physician has initiated Infliximab treatment for the first time (10 Subjects):
- •Clinical diagnosis of Ulcerative Colitis
- •Above age 7 and younger than age 18
- •Signed informed consent statement and assent statement.
- •Healthy Controls (10 Subjects):
- •Above age 7 and younger than age 18
- •otherwise healthy, with no intercurrent illness as determined by a member of the study team using the eligibility checklist
- •controls will be gender and age (± 2 years) matched to the patient groups described above
- •Signed informed consent statement and assent statement
排除标准
- •unwilling to give consent for this study.
- •child with prior prescription and administration of Infliximab
结局指标
主要结局
This study hopes to assess the relative levels of the Stat4a and Stat4β isoforms in PBMCs from patients with Crohn's Disease, ulcerative colitis, or from control patients.
时间窗: Total duration of treatment will be 20-24 weeks (Arm A and Arm B) or 50-54 weeks (Arm C/ Arm D).
次要结局
未报告次要终点
研究者
研究点 (2)
Loading locations...
相似试验
已完成
不适用
STAT4 in Multiple Sclerosis by PCR and Flow CytometryMultiple SclerosisNCT03893344Assiut University104
已完成
不适用
IgG-4 Levels in Systemic SclerosisSystemic SclerosisNCT04219592Meir Medical Center154
已完成
4 期
Differences in Atorvastatin Metabolite Ratios as a Diagnostic Tool in Detecting Atorvastatin Induced MyotoxicityMuscular DiseasesNCT00199745Oslo University Hospital53
已完成
2 期
4-Dimensional CT Derived Ventilation Versus SPECT Aerosol Ventilation in Patients With Thoracic MalignanciesLung CancerEsophageal CancerNCT00531180M.D. Anderson Cancer Center31
终止
1 期
A Study to Evaluate the Effects of ASA404 Alone or in Combination With Taxane-based Chemotherapies on the Pharmacokinetics of Drugs in Patients With Advanced Solid Tumor MalignanciesSolid Tumor MalignanciesNCT01290380Novartis Pharmaceuticals54